Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 39,038	$ 71,902
Marketable securities	97,366	0
Grants and accounts receivables, net	903	732
Income tax receivable	1,715	0
Prepaid expenses and other, net	1,996	1,281
Total current assets	141,018	73,915
Property and equipment, net	7,246	2,277
Intangibles, net	3,912	4,357
Goodwill	20,626	24,041
Investments in common stock	112,008	10,000
Equity method investments	58,119	0
Long-term assets held for sale	0	26,619
Other, net	590	332
Total assets	343,519	141,541
Current liabilities:
Accounts payable	1,339	1,656
Accrued payroll and related	2,361	1,825
Current portion of deferred compensation	891	1,893
Accrued expenses	3,927	867
Acquisition consideration payable	12,000	0
Derivative liability	5,520	0
Current portion of debt	4,835	3,316
Total current liabilities	30,873	9,557
Long-term debt	4,394	8,830
Deferred compensation	12	796
Deferred tax liabilities	49,341	1,709
Long-term liabilities held for sale	0	10,837
Deferred revenue	110,900	1,024
Deferred rent and other	7,061	75
Total liabilities	$ 202,581	$ 32,828
Commitments and contingencies
Equity:
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding	$ 0	$ 0
Common stock, $0.0001 par value; 750,000,000 shares authorized and 37,771,459 and 36,184,912 shares issued and outstanding at December 31, 2015 and 2014, respectively	4	4
Additional paid-in capital	184,898	176,227
Accumulated other comprehensive income	73,579	0
Accumulated deficit	(113,329)	(67,518)
Total Sorrento Therapeutics, Inc. stockholders' equity	145,152	108,713
Noncontrolling interests	(4,214)	0
Total equity	140,938	108,713
Total liabilities and equity	$ 343,519	$ 141,541